GW&K Investment Management LLC Decreases Stock Holdings in Azenta, Inc. (NASDAQ:AZTA)

GW&K Investment Management LLC cut its holdings in shares of Azenta, Inc. (NASDAQ:AZTA - Free Report) by 16.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,299,082 shares of the company's stock after selling 257,794 shares during the quarter. GW&K Investment Management LLC owned about 2.84% of Azenta worth $64,955,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of AZTA. Nisa Investment Advisors LLC lifted its position in Azenta by 1.9% in the third quarter. Nisa Investment Advisors LLC now owns 36,710 shares of the company's stock valued at $1,778,000 after buying an additional 700 shares during the last quarter. Farther Finance Advisors LLC lifted its holdings in shares of Azenta by 20.0% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,537 shares of the company's stock worth $74,000 after acquiring an additional 256 shares during the last quarter. QRG Capital Management Inc. lifted its holdings in shares of Azenta by 6.6% in the 3rd quarter. QRG Capital Management Inc. now owns 6,156 shares of the company's stock worth $298,000 after acquiring an additional 383 shares during the last quarter. State of New Jersey Common Pension Fund D boosted its position in shares of Azenta by 9.5% during the 3rd quarter. State of New Jersey Common Pension Fund D now owns 40,008 shares of the company's stock worth $1,938,000 after purchasing an additional 3,469 shares during the period. Finally, Versor Investments LP increased its holdings in Azenta by 199.1% in the 3rd quarter. Versor Investments LP now owns 15,697 shares of the company's stock valued at $760,000 after purchasing an additional 10,449 shares during the last quarter. 99.08% of the stock is owned by institutional investors and hedge funds.

Azenta Price Performance

Shares of NASDAQ AZTA traded down $0.15 during mid-day trading on Tuesday, hitting $40.96. The company had a trading volume of 694,387 shares, compared to its average volume of 518,000. The company has a market capitalization of $1.87 billion, a PE ratio of -13.74 and a beta of 1.47. The business's 50-day simple moving average is $49.99 and its 200 day simple moving average is $47.61. Azenta, Inc. has a 1-year low of $38.82 and a 1-year high of $67.77.

Azenta (NASDAQ:AZTA - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $0.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.05 by $0.03. Azenta had a positive return on equity of 1.25% and a negative net margin of 24.91%. On average, analysts expect that Azenta, Inc. will post 0.53 EPS for the current year.

Wall Street Analysts Forecast Growth

AZTA has been the topic of a number of research reports. Needham & Company LLC upped their price target on Azenta from $55.00 to $59.00 and gave the stock a "buy" rating in a research note on Thursday, February 6th. TD Cowen raised Azenta to a "hold" rating in a research note on Thursday, February 27th. Stephens restated an "overweight" rating and set a $60.00 target price on shares of Azenta in a report on Thursday, January 2nd. Finally, Evercore ISI boosted their price target on shares of Azenta from $50.00 to $52.00 and gave the stock an "in-line" rating in a research note on Thursday, February 6th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat, Azenta currently has an average rating of "Hold" and an average target price of $58.75.

Azenta Company Profile

Azenta, Inc provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services.